Vaccines Europe Manifesto

Vaccines Europe launched a Manifesto calling for action of European policy makers to harness the 2017-2019 momentum on vaccination and protect European citizens against vaccine-preventable diseases

Find out how

The EU Vaccine Industry in Figures

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.

Find out more

Vaccines: a tool for spending smart

Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation

Find out how

-->

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News

RSS

Early Career Research Prize in Vaccinology R&D – 3rd edition

2019 06 12 Written by Vaccines Europe

The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The 2019 Prize edition aims at rewarding significant achievements in Vaccines R&D in Europe.

The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of immune responses, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).

For information regarding application criteria, follow this link.

Vaccines Europe Statement on influenza vaccine supply in the 2019-20 Northern Hemisphere season

2019 04 30 Written by Vaccines Europe

The World Health Organization (WHO) recommendations for the viruses to be included in influenza vaccines each season provide critical guidance to national public health authorities, regulatory agencies and vaccine manufacturers in advance of development and production.

During the 21st February 2019 meeting (Beijing, China), the WHO postponed the recommendation of the A (H3N2) strain candidate. One month later, on the 21st of March 2019, the WHO recommended the A(H3N2) vaccine strain for the Northern Hemisphere 2019-2020 season. This was an A/Kansas/14/2017 (H3N2)-like virus (see link for the WHO 2019-2020 strain recommendation).

In line with the published statement of the International Federation of Pharmaceutical Manufacturers & Associations, IFPMA (see link for the IFPMA statement), Vaccines Europe (VE) would also like to reiterate that protecting public health through annual seasonal influenza vaccination campaigns and achieving vaccination coverage goals are critical. Following the WHO’s recommendations, it takes approximately 6-8 months to produce and approve the full global supply of influenza vaccines. VE encourages National Health Authorities to continue preparing their influenza vaccination campaigns, mindful of potential changes to the campaign start and end dates, given the late WHO announcement on A/H2N3 strain candidate.

As a longstanding public health partner in the field, VE and its members are closely cooperating with European and National Regulatory Authorities to minimise any potential delays and provide a sustainable and timely supply of influenza vaccines for the 2019/20 season.

Health industries welcome unprecedented progress leading to an adoption of Horizon Europe, its areas for missions and partnerships

2019 04 17 Written by Vaccines Europe

17 April 2019

The six undersigned European health industry associations representing small and large companies welcome the Council and the European Parliament agreement on the Horizon Europe legislation, including areas for partnerships and missions, which clearly demonstrates Europe’s commitment to research and innovation.

We welcome the overall structure and ambition of Horizon Europe. Europe has been at the forefront of life science research and a health mission is a palpable signal that it intends to keep on striving for excellence and impact. The challenges identified in the Horizon Europe “Health” cluster, with activities across the whole research and innovation spectrum, are centred on relevance and impact for patients and society. Read more…

Vaccines Europe Manifesto

2019 03 06 Written by Vaccines Europe

PRESS STATEMENT

6 March 2019 – Brussels, Belgium: Vaccines Europe launched a Manifesto today calling for action of European policy makers to harness the 2017-2019 momentum on vaccination and protect European citizens against vaccine-preventable diseases.

Access the manifesto here.

The manifesto outlines the three visions of the innovative vaccine industry in Europe:

Health for all, highlighting the importance of vaccination throughout the life-span and role of all healthcare professionals in informing their patients about the importance of vaccination as well as being vaccinated themselves; 

European excellence, proving the innovative vaccine industry should stay in Europe and what role existing and new vaccines have to play in the fight against AMR; and 

Stronger together, summarising the benefits of sustainable vaccine supply and demand ecosystem in Europe and the importance of e-health for national immunisation programmes.

The manifesto highlights the importance of cooperation of all stakeholders in addressing vaccine and vaccination issues in Europe. It lays out the asks of the European-based innovative vaccine industry, a stakeholder who has a role to play in the ongoing EU initiatives on vaccination.

Read more…

See all News